Ulrich Keilholz

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

The paper identifies genomic and transcriptomic features of telomere maintenance mechanisms in complex karyotype sarcomas, linking ALT status to therapeutic vulnerabilities.

The paper identifies non-covalent inhibitors of PRDX5, a protein upregulated in MPM, through a machine learning guided pipeline and biochemical validation, suggesting it as a therapeutic target.

This study shows that extracellular circadian communication coordinates the circadian clock and cell cycle, and its disruption impairs tissue growth and links circadian disruption to oncogenic processes.

This study identifies circadian clock subtypes in breast cancer and shows their impact on drug sensitivity.

This study identifies optimal drug treatment times by analyzing circadian rhythms and drug responses in cancer cells using high-throughput deep phenotyping.

preon normalizes drug names and cancer types in large-scale data for precision oncology.